Femasys Inc (FEMY)vsWest Pharmaceutical Services Inc (WST)
FEMY
Femasys Inc
$0.51
-0.06%
HEALTHCARE · Cap: $33.17M
WST
West Pharmaceutical Services Inc
$247.02
+0.71%
HEALTHCARE · Cap: $17.68B
Smart Verdict
WallStSmart Research — data-driven comparison
West Pharmaceutical Services Inc generates 149020% more annual revenue ($3.07B vs $2.06M). WST leads profitability with a 16.1% profit margin vs 0.0%. WST earns a higher WallStSmart Score of 55/100 (C-).
FEMY
Avoid23
out of 100
Grade: F
WST
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FEMY.
Margin of Safety
-256.8%
Fair Value
$68.99
Current Price
$247.02
$178.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 31.4% year-over-year
Safe zone — low bankruptcy risk
Strong operational efficiency at 21.6%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -3.8% — below average capital efficiency
Premium valuation, high expectations priced in
2.1% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : FEMY
The strongest argument for FEMY centers on Revenue Growth. Revenue growth of 31.4% demonstrates continued momentum.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 16.1% and operating margin at 21.6%.
Bear Case : FEMY
The primary concerns for FEMY are EPS Growth, Market Cap, Profit Margin.
Bear Case : WST
The primary concerns for WST are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
FEMY profiles as a hypergrowth stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.18 — expect wider price swings.
FEMY is growing revenue faster at 31.4% — sustainability is the question.
WST generates stronger free cash flow (175M), providing more financial flexibility.
Bottom Line
WST scores higher overall (55/100 vs 23/100), backed by strong 16.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Femasys Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Femasys Inc. is an innovative medical technology firm at the forefront of transforming women's healthcare through its proprietary solutions aimed at diagnosing and treating gynecological conditions. The company is particularly recognized for its flagship products that offer non-surgical alternatives for common issues such as uterine fibroids and contraception, positioning it as a leader in the evolving landscape of women's health. As demand for minimally invasive procedures grows, Femasys is strategically positioned to capitalize on this trend, enhancing patient outcomes while optimizing healthcare delivery. With a commitment to addressing significant unmet needs in women's health, Femasys aims to revolutionize the standards of care in this vital sector.
West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?